NAD+ vs Resveratrol: Comparing the Indexed Record
Two compounds, two separate research records. This reference sets NAD+ and Resveratrol against each other on parameters a laboratory can independently verify.
Side-by-side research profile
| Parameter | NAD+ | Resveratrol |
|---|---|---|
| PubMed indexed records | 76,583 | 21,647 |
| Registered studies (ClinicalTrials.gov) | 749 | 253 |
| Literature depth | Extensive | Extensive |
| Handling class | Lyophilised powder | Lyophilised powder |
| Designation | Research use only | Research use only |
Compound profiles
NAD+ in the indexed record
Indexed output for NAD+ stands at 76,583 records, an extensive literature, alongside 749 registered studies on ClinicalTrials.gov.
Publications carrying this compound include Cell Metab, EMBO Mol Med, Nat Metab, spanning 2020–2024.
- NAD(+) metabolism and its roles in cellular processes during ageing — Nat Rev Mol Cell Biol, 2021. PMID: 33353981
- NAD(+) metabolism, stemness, the immune response, and cancer — Signal Transduct Target Ther, 2021. PMID: 33384409
- NAD(+) homeostasis in health and disease — Nat Metab, 2020. PMID: 32694684
- NAD(+) homeostasis in human health and disease — EMBO Mol Med, 2021. PMID: 34041853
Resveratrol in the indexed record
Resveratrol returns 21,647 indexed records on PubMed, an extensive record, alongside 253 registered studies on ClinicalTrials.gov.
Recent indexed work appears in Ann N Y Acad Sci, Cancer Lett, Curr Top Med Chem, spanning 2011–2022.
- Resveratrol for cancer therapy: Challenges and future perspectives — Cancer Lett, 2021. PMID: 34052324
- Bioavailability of resveratrol — Ann N Y Acad Sci, 2011. PMID: 21261636
- The impact of resveratrol on skin wound healing, scarring, and aging — Int Wound J, 2022. PMID: 33949795
- Resveratrol: a review of plant sources, synthesis, stability, modification and food application — J Sci Food Agric, 2020. PMID: 31756276
How the literature differs
The indexed record is not symmetrical between these two compounds. NAD+ carries 54,936 more indexed records than Resveratrol, which means published methodology, characterisation data and replication attempts are more readily located for NAD+. For a researcher planning a literature review, that asymmetry usually determines which compound has established reference protocols and which requires primary-source work.
Registered study counts (749 vs 253) track a different signal — formal study registration rather than published output — and the two figures frequently diverge.
Classification and why it matters
NAD+ and Resveratrol sit in different structural classes, and that classification is what determines whether a published protocol for one has any bearing on the other. Peptide research compounds are grouped by sequence length, origin and the receptor families the literature associates with them — not by the outcome a reader might be looking for.
Reading across classes is the most common error in a literature review. A protocol developed for NAD+ describes conditions validated for NAD+: concentration ranges, solvent choice, incubation windows and control selection were all established against that compound. Applying those same conditions to Resveratrol without re-validation produces data that cannot be compared back to the source publication.
Where the two compounds are studied in overlapping models, the published work almost always treats them as separate arms rather than as substitutes. That separation is the useful signal: it indicates the research record does not consider them equivalent.
Storage and stability
Lyophilised peptide is the stable form. Held sealed at -20°C and shielded from light, it tolerates long storage; once reconstituted that tolerance drops sharply and the working solution is treated as short-lived.
Each freeze-thaw cycle costs integrity, which is why reconstituted material is normally split into single-use aliquots.
Selecting between them for a study design
NAD+ and Resveratrol are not interchangeable. They differ in structural class and in the pathways the literature associates with each, so substituting one for the other changes what a model is actually measuring.
Where a protocol cites a specific compound, the cited compound is the one the published result applies to. Where no protocol exists, the compound with the deeper indexed record (NAD+) generally offers more methodological precedent.
Verification and documentation
What is in the vial is established by lot-specific analytics, not by label text. HPLC gives purity as a share of total peak area; mass spectrometry confirms the molecular weight matches the intended sequence. Neither substitutes for the other.
Frequently asked questions
Are NAD+ and Resveratrol the same compound?
No. They are structurally distinct research compounds with separate literature records — 76,583 indexed records for NAD+ and 21,647 for Resveratrol.
What is the regulatory status of these compounds?
Neither is an approved drug. Both are supplied strictly for in-vitro laboratory research and are not intended for human or veterinary consumption.
Which of NAD+ or Resveratrol has more published research?
NAD+, with 76,583 indexed PubMed records against 21,647.
Related references
- NAD+ — product and lot documentation
- Certificate of analysis & purity testing
- Research reference index
Research use only. The compounds discussed are supplied for in-vitro laboratory research. They are not drugs, are not approved for the diagnosis, treatment, cure or prevention of any condition, and are not intended for human or veterinary consumption.